State Street Corp Increases Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

State Street Corp grew its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 6.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 449,975 shares of the biotechnology company’s stock after purchasing an additional 27,147 shares during the period. State Street Corp owned about 2.12% of Enanta Pharmaceuticals worth $4,662,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ENTA. Allspring Global Investments Holdings LLC purchased a new stake in Enanta Pharmaceuticals during the second quarter worth $35,000. US Bancorp DE raised its position in shares of Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 4,243 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth about $122,000. Quest Partners LLC grew its position in shares of Enanta Pharmaceuticals by 511.2% during the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after acquiring an additional 9,692 shares during the period. Finally, Valence8 US LP purchased a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $207,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ:ENTA opened at $6.01 on Monday. Enanta Pharmaceuticals, Inc. has a 1 year low of $5.70 and a 1 year high of $17.80. The firm has a market capitalization of $127.38 million, a PE ratio of -1.10 and a beta of 0.49. The business’s 50 day moving average price is $9.15 and its 200-day moving average price is $11.46.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The firm had revenue of $14.60 million during the quarter, compared to analysts’ expectations of $17.99 million. During the same quarter in the previous year, the business posted ($1.33) EPS. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. As a group, analysts expect that Enanta Pharmaceuticals, Inc. will post -4.73 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. HC Wainwright cut their price target on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, December 24th. Finally, Robert W. Baird decreased their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $17.25.

Insider Transactions at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 13.64% of the company’s stock.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.